Pre-announcement of the Key Financial Results for Third Quarter 2025 and Revised Guidance for 2025

About this update from Bioporto A/s

[{"type":"image","alt":"BioPorto A/S","displaySize":"","headline":null,"caption":"BioPorto A/S","className":"","disableSlideshowImg":false,"size":{"original":{"width":1280,"height":720,"url":"https://media.zenfs.com/en/globenewswire.com/b7c79bb76fefe5d65277db64dd9691c8"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Sh1hlk4k7.wyKDRvmzFJUA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTU0MDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/b7c79bb76fefe5d65277db64dd9691c8","width":960,"height":540},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/UY7JRvIvfZQJ5av4ihgVmQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD0xMzUwO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/b7c79bb76fefe5d65277db64dd9691c8","width":1200,"height":675}},"lazy":false},{"type":"text","content":"November 4, 2025                                                Announcement no. 22","length":324,"tagName":"p"},{"type":"text","content":"Pre-announcement of the Key Financial Results for Third Quarter 2025 and Revised Guidance for 2025 ","length":98,"tagName":"p"},{"type":"text","content":"Copenhagen, Denmark, November 4, 2025, (GLOBE NEWSWIRE) – BioPorto A/S (“BioPorto” or the “Company”) (CPH:BIOPOR), today pre-announced the key financial results for the third quarter of 2025 and revised guidance for 2025.","length":221,"tagName":"p"},{"type":"text","content":"Key Financial Results for Q3 2025 reflect Continued NGAL Sales Growth ","length":69,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Revenue in the third quarter of 2025 totaled DKK 10.4 million, representing a 7% increase compared to the same period last year, and a 10% increase at constant exchange rates. NGAL sales totaled DKK 7.2 million, growing by 5% globally, and by 10% at constant exchange rates.","length":274,"tagName":"p"}]},{"val":[{"type":"text","content":"Strong US NGAL Research Use Only (RUO) sales growth of 20% compared to the third quarter of 2024. At constant exchange rates, US NGAL RUO sales increased by 27%.","length":161,"tagName":"p"}]},{"val":[{"type":"text","content":"ProNephro AKI™ (NGAL) sales through distributors in the third quarter of 2025...

More updates from Bioporto A/s